These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6883351)

  • 1. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
    Staquet MJ; Byar DP; Green SB; Rozencweig M
    Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on "clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
    Martin DS; Stolfi RL; Sawyer RC
    Cancer Treat Rep; 1984 Nov; 68(11):1317-8. PubMed ID: 6498852
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
    Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
    Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
    Leopold WR; Nelson JM; Plowman J; Jackson RC
    Cancer Res; 1985 Nov; 45(11 Pt 1):5532-9. PubMed ID: 4053027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitumor activity of cis-dichlorodiammineplatinum(II).
    Wolpert-DeFilippes MK
    Cancer Treat Rep; 1979; 63(9-10):1453-8. PubMed ID: 498146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic drugs as potential antitumor agents: a selective screening study.
    Driscoll JS; Melnick NR; Quinn FR; Lomax N; Davignon JP; Ing R; Abott BJ; Congleton G; Dudeck L
    Cancer Treat Rep; 1978 Jan; 62(1):45-74. PubMed ID: 23898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor screening procedures of the National Cancer Institute.
    Schepartz SA
    Jpn J Antibiot; 1977 Dec; 30 Suppl():35-40. PubMed ID: 612710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental evaluation of anthracycline analogs.
    Casazza AM
    Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human tumor testsystems: a new screening approach.
    Kraemer HP; Sedlacek HH
    Behring Inst Mitt; 1986 Jun; (80):103-12. PubMed ID: 3753367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
    Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and evaluation of anticancer agents.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical antitumor activity of bizelesin in mice.
    Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
    Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of nude mouse-human cancer xenograft system for sensitivity test of anticancer drugs].
    Fujita M; Taguchi T
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):606-15. PubMed ID: 7184418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.